FAQ

Poly(ADP-ribose) Polymerase Inhibitors

Known as: Poly (ADP-Ribose) Polymerase Inhibitor, PARP Inhibitors, PARP inhibitor 
A substance that blocks an enzyme involved in many functions of the cell, including the repair of DNA damage. DNA damage may be caused by normal cell… (More)

Topic mentions per year

Topic mentions per year

1986-2017
05010015019862017

Related topics

Related topics

23 relations

Narrower (14)

1,5-dihydroisoquinoline1,5-dihydroxyisoquinoline3-aminobenzamide3-methoxybenzamide
(More)
In BloodPARP1 protein, humanPoly(ADP-Ribose) Polymerase Inhibitor [EPC]Poly(ADP-Ribose) Polymerase Inhibitors [MoA]
(More)

Related mentions per year

Related mentions per year

1946-2018
19401960198020002020
Poly(ADP-ribose) Polymerase Inhibitors
chemical synthesis
PARP1 protein, human
3-aminobenzamide
olaparib
standards characteristics

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1…
PURPOSE Olaparib (AZD2281), an orally active poly (ADP-ribose) polymerase inhibitor that induces synthetic lethality in BRCA1- or… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.
PURPOSE Selective tumor cell cytotoxicity can be achieved through a synthetic lethal strategy using poly(ADP)-ribose polymerase… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells.
Poly(ADP-ribose) (PAR) polymerase 1 (PARP1) is activated by DNA single-strand breaks (SSB) or at stalled replication forks to… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.
PURPOSE We conducted the first phase 0 clinical trial in oncology of a therapeutic agent under the Exploratory Investigational… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016.
PURPOSE Poly (ADP-ribose) polymerase (PARP) inhibitors are undergoing clinical evaluation for cancer therapy. Because PARP… (More)
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.
PURPOSE One mechanism of tumor resistance to cytotoxic therapy is repair of damaged DNA. Poly(ADP-ribose) polymerase (PARP)-1 is… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial.
Poly(ADP-ribose) polymerase (PARP)-1 (EC 2.4.2.30) is a nuclear enzyme that promotes the base excision repair of DNA breaks… (More)
  • figure 1
  • table 1
  • table 1
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair
Poly (ADP-ribose) polymerase (PARP-1), ATM and DNA-dependent protein kinase (DNA-PK) are all involved in responding to DNA damage… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2005
2005
Low-dose poly(ADP-ribose) polymerase inhibitor-containing combination therapies reverse early peripheral diabetic neuropathy.
Poly(ADP-ribose) polymerase (PARP) inhibition has recently been identified as a novel approach to treatment of experimental… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure.
Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of… (More)
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 5
Is this relevant?